hospital covid-19 death Ventilators SOLIDARITY patient

WHO trial finds no benefit of 4 drugs for hospital COVID patients

Reading now: 821
www.cidrap.umn.edu

None of the four once-promising drugs evaluated for the treatment of COVID-19 in the ongoing World Health Organization (WHO) Solidarity Trial—remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a—prevented in-hospital death, reduced the need for ventilation, or shortened the duration of hospitalization.

The interim results of the open-label study, published yesterday in the New England Journal of Medicine, involved randomly assigning hospitalized COVID-19 patients equally to whichever trial drugs were available locally or to a control group from Mar 22 to Oct 4.All four drugs were already in use for other indications and had been repurposed as potential treatments for the novel coronavirus.Advanced age, early need for ventilation

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA